ZILA Zila (MM)

Zila, Inc. (NASDAQ:ZILA) today announced that Frank J. Bellizzi, DMD, president of Zila Pharmaceuticals, will present a company overview at the 20th Annual Roth Capital Partners Growth Stock Conference on Tuesday, February 19 at 4:00 p.m. Pacific Time at The Ritz-Carlton in Laguna Niguel, California. Interested parties may listen to the webcast of this presentation by visiting the company�s website at www.zila.com. Listeners are encouraged to visit the website at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. For those unable to listen to the live webcast, the presentation will be archived on the same Web site for 30 days. About Zila: Zila is a fully integrated oral diagnostic company dedicated to the prevention, detection and treatment of oral disease, with a primary focus on oral cancer. ViziLite� Plus, the company's flagship product for the early detection of oral abnormalities that could lead to cancer, is the first and only adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer. In addition, Zila designs, manufactures and markets a suite of proprietary products sold exclusively and directly to dental professionals for periodontal disease, including the Rota-dent(R) Professional Powered Brush, the Pro-Select(R) Platinum ultrasonic scaler and a portfolio of oral pharmaceutical products for both in-office and home-care use. For more information about the company and its products, please visit www.zila.com.